Erum sits down with Michael Heltzen, CEO of eXoZymes, to dive into the transformative world of cell-free biomanufacturing. Michael shares the origin story of ExoZymes—from a student bioengineering dream at UCLA to ringing the NASDAQ bell—and unpacks why scalability, sustainability, and design thinking are central to the next generation of biotech. If you're curious about how biology can be engineered without living cells, what it takes to commercialize breakthrough science, or how new business models in synthetic biology are emerging, this is the episode for you. Get ready to rethink what’s possible when biology breaks free from the cell wall.Grow Everything brings the bioeconomy to life. Hosts Karl Schmieder and Erum Azeez Khan share stories and interview the leaders and influencers changing the world by growing everything. Biology is the oldest technology. And it can be engineered. What are we growing?Learn more at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.messaginglab.com/groweverything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Chapters:00:00:00 – Unlocking a New Era: Rethinking Natural Resources for the Future00:00:17 – SynBioBeta Afterglow: Late Nights, Big Ideas, and Bio Buzz00:02:39 – Breaking the Cell Wall: The Power of Cell-Free Biomanufacturing00:03:33 – Meet Michael Heltzen: The Visionary Behind the Next Bio Revolution00:09:54 – Inside NCTX: The Molecule That Might Change Everything00:16:06 – No Scale, No Impact: Tackling SynBio’s Toughest Bottlenecks00:26:43 – From Supplements to Cures: Bio’s Leap Across Sectors00:27:19 – AI x Enzymes: Cracking Nature’s Code in Real Time00:28:06 – Making Biology Predictable: ML Meets Molecular Design00:30:14 – Faster Than Nature: How AI Shrinks Production Timelines00:33:29 – Go-to-Market Moves: Biotech Strategy for the Real World00:36:07 – Bio Click™: Targeted Enzymes with Industrial Precision00:38:38 – Life After the Bell: IPOs, Growth, and Big Bio Energy00:42:29 – Zooming Out: Big-Picture Thinking for What Comes NextLinks and Resources:eXoZymesNCTx BioClick⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Topics Covered: biomanufacturing, cell free biomanufacturing, enzymes, nutraceuticals, biotech, pharmaceuticals, AI, spinoutsHave a question or comment? Message us here:Text or Call (804) 505-5553 ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ / ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Grow Everything⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Email: [email protected] by: NihiloreProduction by: Amplafy Media

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related